Peter has worked in the Gene and Cell Therapy space for over 10 years and has significant experience in manufacturing and CMC product development.
Prior to ElevateBio, Peter lead both the Drug Product MS&T group and CMC team for the Lenti-D Gene Therapy program for the Treatment of Cerebral Adrenoleukodystrophy (CALD) at bluebird bio for more than four years. In his MS&T role, he completed multiple late-phase global technology transfers and led the drug product process validation efforts instrumental to filing the Marketing Authorization Application (MAA) for Zynteglo. Peter also held various roles at the Connell O’Reilly Cell Manipulation Core Facility (CMCF) at Dana Farber Cancer Institute (DFCI), assisting in the development and manufacturing of gene and cell based therapies for conditions such as melanoma, MDS/AML, ALS, SCID-X1, and Wiskott Aldrich Syndrome (WAS).
Education & Accomplishments
Peter received his bachelor’s degree in Biology from Springfield College.
Interested in working with people like Audra? We’re looking for pioneers and innovative thinkers committed to developing the next-generation of cell and gene therapies. Review our open roles and find your future.